Cervical Cancer Screening

Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria:

  • Women age 21-64 who had cervical cytology performed within the last 3 years
  • Women 30–64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years
  • Women age 30-64 who had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last 5 years

Date Reviewed: January 27, 2022

Measure Info

MIPS 309 NQF 0032 CMS 309 NQF Endorsed
Measure Type
Measure Steward
National Committee for Quality Assurance
Clinical Topic Area
Cancer Screening
Prevention and Wellness
Women's Preventive Services

Care Setting
Data Source
Electronic Health Records

The PMC believes that the Cervical Cancer Screening is an important measure, given its ability to impact disease prevention. Current evidence supports this measure, and it does not increase clinician burden or have any feasibility issues. The measure specifications need clarity; the PMC recommends revising the specifications for better interpretation of the age appropriate screening tests. To avoid unnecessary screening, the PMC encourages the development of an overuse measure.